The PBS listing for guselkumab (Tremfya) has been extended to include adults with active psoriatic arthritis The selective IL-23 inhibitor targeting the p19 subunit has previously only been reimbursed for moderate to severe plaque psoriasis. The listing for psoriatic arthritis is based on results from the DISCOVER trials, as previously reported in the limbic. DISCOVER ...
PBS listing for guselkumab extended to active psoriatic arthritis
By Mardi Chapman
6 Jul 2021